AR082444A1 - Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa - Google Patents

Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa

Info

Publication number
AR082444A1
AR082444A1 ARP110102783A ARP110102783A AR082444A1 AR 082444 A1 AR082444 A1 AR 082444A1 AR P110102783 A ARP110102783 A AR P110102783A AR P110102783 A ARP110102783 A AR P110102783A AR 082444 A1 AR082444 A1 AR 082444A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulation
phosphodesterase
inhibitor
branched
linear
Prior art date
Application number
ARP110102783A
Other languages
English (en)
Inventor
Sauro Bonelli
Elena Losi
Enrico Zambelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR082444A1 publication Critical patent/AR082444A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una formulación farmacéutica para una administración en aerosol, caracterizada porque comprende el (-) enantiómero de un compuesto de la fórmula general (1) en donde n es 0 o 1; R1 y R2 pueden ser iguales o diferentes y se seleccionan del grupo que consiste en alquilo C1-6 lineal o ramificado, sustituido opcionalmente con uno o más átomos de halógeno; -OR3 en donde R3 es un alquilo C1-6 lineal o ramificado sustituido opcionalmente con uno o más átomos de halógeno o grupos cicloalquilo C3-7; y -HNSO2R4 en donde R4 es un alquilo C1-4 lineal o ramificado sustituido opcionalmente con uno o más átomos de halógeno, en donde al menos uno de R1 y R2 es HNSO2R4 y un propelente.Reivindicación 10: Un inhalador de cartucho presurizado (pMDl) caracterizado porque contiene a la formulación de acuerdo con cualquiera de las reivindicaciones 1 a 9. Reivindicación 13: Un vial, caracterizado porque es de dosis única o de múltiples dosis de la formulación de acuerdo con las reivindicaciones 11 ó 12 para su administración usando un aparato nebulizador adecuado.
ARP110102783A 2010-08-03 2011-08-02 Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa AR082444A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171734 2010-08-03

Publications (1)

Publication Number Publication Date
AR082444A1 true AR082444A1 (es) 2012-12-05

Family

ID=43301924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102783A AR082444A1 (es) 2010-08-03 2011-08-02 Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa

Country Status (10)

Country Link
US (1) US9358224B2 (es)
EP (2) EP2600829B1 (es)
KR (1) KR101803121B1 (es)
CN (2) CN103052378A (es)
AR (1) AR082444A1 (es)
BR (1) BR112013002504A2 (es)
CA (1) CA2807406C (es)
ES (1) ES2628891T3 (es)
RU (1) RU2578975C2 (es)
WO (1) WO2012016845A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
PE20121467A1 (es) * 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
BR112013002506A2 (pt) 2010-08-03 2016-05-31 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco inalável, inalador de pó seco inalável e embalagem
CN103562185A (zh) 2011-06-06 2014-02-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
KR20150079745A (ko) 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
CA2897464C (en) * 2013-01-28 2021-05-18 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US20160030435A1 (en) * 2013-03-15 2016-02-04 Robert I HENKIN Phosphodiesterase inhibitor treatment
RS65452B1 (sr) * 2013-10-22 2024-05-31 Chiesi Farm Spa Postupak za pripremu pde4 inhibitora
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP4106722A1 (en) * 2020-02-20 2022-12-28 Chiesi Farmaceutici S.p.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
ES2342842T3 (es) * 2005-06-06 2010-07-15 F. Hoffmann-La Roche Ag Derivados de sulfamida utiles como inhibidores de la carniti-na-palmitoil-transferasa de higado (l-cpt1).
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
WO2008006509A1 (en) 2006-07-14 2008-01-17 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
BR112013002506A2 (pt) 2010-08-03 2016-05-31 Chiesi Farma Spa formulação em pó seco inalável, uso de uma formulação em pó seco inalável, inalador de pó seco inalável e embalagem

Also Published As

Publication number Publication date
CN103052378A (zh) 2013-04-17
EP2600829A2 (en) 2013-06-12
CA2807406A1 (en) 2012-02-09
RU2578975C2 (ru) 2016-03-27
WO2012016845A3 (en) 2012-04-12
KR101803121B1 (ko) 2017-11-29
ES2628891T3 (es) 2017-08-04
BR112013002504A2 (pt) 2016-05-31
US20120034172A1 (en) 2012-02-09
WO2012016845A2 (en) 2012-02-09
CN106377503A (zh) 2017-02-08
EP3143987A1 (en) 2017-03-22
RU2013104401A (ru) 2014-08-10
EP2600829B1 (en) 2017-06-14
CA2807406C (en) 2018-12-11
KR20130094782A (ko) 2013-08-26
US9358224B2 (en) 2016-06-07

Similar Documents

Publication Publication Date Title
AR082444A1 (es) Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
AR082443A1 (es) Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
ECSP12012174A (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
CO7160104A2 (es) Inhibidores de virus de hepatitis c
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
UY33501A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
UY34491A (es) La composición herbicida que contiene ácido de 4-amino-3-cloro-6- (4-cloro-2-flúor-3-metoxifenil) pyridina-2-carboxílico o los derivados de los mismos y fluroxipir o los derivados de los mismos
AR091682A1 (es) Combinaciones de principios activos fungicidas e insecticidas
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
SA520412289B1 (ar) مركبات مثبط الهدف الميكانيكي للراباميسين
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas

Legal Events

Date Code Title Description
FC Refusal